These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12490775)

  • 1. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.
    Liu CY; Chiu NY; Wu CK; Yuan LM; Hsiao MC; Liao O
    Int Clin Psychopharmacol; 2003 Jan; 18(1):49-51. PubMed ID: 12490775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical antipsychotics and cognition in schizophrenia.
    Sharma T
    Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
    J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
    Ho BC; Miller D; Nopoulos P; Andreasen NC
    J Clin Psychiatry; 1999 Oct; 60(10):658-63. PubMed ID: 10549681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of antipsychotic drugs.
    Messori A
    Am J Psychiatry; 2003 Mar; 160(3):591-2; author reply 592-3. PubMed ID: 12611854
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
    Kasper S; Hale A; Azorin JM; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative effectiveness of antipsychotic drugs.
    Meibach RC
    Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract]   [Full Text] [Related]  

  • 10. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.
    Procyshyn RM; Zerjav S
    Clin Ther; 1998; 20(6):1203-17; discussion 1192-3. PubMed ID: 9916613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
    Aguglia E; De Vanna M; Onor ML; Ferrara D
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1229-33. PubMed ID: 12502008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.
    Noordsy DL; Glynn SM; Sugar CA; O'Keefe CD; Marder SR
    J Psychiatr Res; 2017 Dec; 95():299-307. PubMed ID: 28942217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients.
    Briken P; Nika E; Moritz S; Haasen C; Perro C; Yagdiran O; Naber D; Krausz M
    Schizophr Res; 2002 Oct; 57(2-3):311-3. PubMed ID: 12223264
    [No Abstract]   [Full Text] [Related]  

  • 15. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
    Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
    Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
    J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.
    Martin H; Slyk MP; Deymann S; Cornacchione MJ
    J Am Med Dir Assoc; 2003; 4(4):183-8. PubMed ID: 12837138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.
    Crocq MA; Leclercq P; Guillon MS; Bailey PE
    Eur Psychiatry; 2002 Sep; 17(5):296-7. PubMed ID: 12381502
    [No Abstract]   [Full Text] [Related]  

  • 19. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 1998 Nov; 13(6):253-62. PubMed ID: 9861575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.